Phase I Study of ETEC Vaccine
Summary
The purpose of this study is to learn if a new candidate vaccine (dmLT) against ETEC (E. coli infection) is safe. This vaccine will be tested to see what effects it has on the body and the ability of the vaccine to help the body resist disease. Researchers want to find the highest dose of dmLT vaccine that can be given without causing severe side effects. Most E. coli bacteria are harmless to humans and can even be beneficial. However, some are harmful, and can cause diarrhea. About 32 healthy adults, ages 18-45, will participate in this study. This study will require volunteers to stay in the research facility for several nights. Participants will be assigned to receive 1 of 4 vaccine doses by mouth. Study procedures include: stool samples, blood samples, and documenting side effects. Participants will be involved in study related procedures for about 8 months.
Timeline
- Start
- 2010-09-13
- Primary completion
- 2012-06-08
- Completion
- 2012-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | double-mutant LT | Vaccine | 5 ug | Oral |
| Subject | double-mutant LT | Vaccine | 25 ug | Oral |
| Subject | double-mutant LT | Vaccine | 50 ug | Oral |
| Subject | double-mutant LT | Vaccine | 100 ug | Oral |